The European Medicines Agency made its determination after examining a small number of clot cases in people vaccinated in the U.S. It said these problems should be considered “very rare side effects of the vaccine.”
The United States will likely move to resume Johnson & Johnson’s COVID-19 vaccine this coming week, possibly with restrictions or broader warnings after reports of some very rare blood clot cases, the government’s top infectious diseases expert said Sunday.
The new effort, which relies on money approved by Congress as part of President Joe Biden’s coronavirus relief package, aims to break what experts say is a feast-or-famine cycle in U.S. preparedness for biological threats, of which the coronavirus is only one example.
Nearly half of American adults have gotten at least one dose of the vaccine, and about 30% of adults in the U.S. have been fully vaccinated, according to the Centers for Disease Control and Prevention.
As many as 60 countries might be stalled at the first shots of their coronavirus vaccinations because nearly all deliveries through the global program intended to help some of the world's poorest nations are blocked until as late as June.
Cuyahoga County’s top health leaders, including Executive Armond Budish and Commissioner Terry Allan, held a briefing on Friday afternoon regarding the region’s progress in rolling out the COVID-19 vaccine.
World Health Organization Director-General Tedros Adhanom Ghebreyesus said that on average, one in four people in rich countries has received at least one dose of a COVID-19 vaccine, compared to only one in 500 people in low-income countries.
A patchwork of advice was emerging from governments across Europe and farther afield, a day after the European Union’s drug regulator said there was a “possible link” between the AstraZeneca vaccine and a rare clotting disorder while reiterating the vaccine is safe and effective.